On March 11, 2026, Ligand Pharmaceuticals CFO Octavio Espinoza sold 3,057 shares of common stock for approximately $688,000, according to an SEC Form 4 filing. This transaction aligns with Espinoza’s recent selling activity, matching the median size of his previous sales since December 2024. Notably, 2,405 shares were acquired through exercised stock options, and the sale represented 12.7% of his direct ownership, leaving him with 21,010 shares valued at around $4.65 million.
This insider sale, executed at a weighted average price of $225.00 per share, exceeded both the opening and closing market prices on that date, indicating favorable pricing. Despite the sale, Ligand’s fundamentals appear strong, with a significant revenue increase from $167.1 million in 2024 to $268.1 million in 2025, driven by a 48% rise in royalty revenue. Management forecasts further growth, projecting up to $285 million in revenue for 2026.
For investors, the key takeaway is that while insider selling may raise questions, it is part of a structured liquidity plan. Ligand’s robust growth trajectory and capital-light model suggest the company remains well-positioned in the biopharmaceutical sector.
Source: fool.com